Rory usually gets his facts wrong. Their is a common member that was on both boards. This was stated in the Montigen buyout analyst meeting. I believe SUPG was made aware of the possible advancements that Montigen's pipeline may have. I also it believe that having this common board member gave Montigen the confidence to partner with SUPg.
Correct, Dr. Daniel Von Hoff worked with both SUPG and Montigen. Word is SUPG looked at nearly 100 drug development companies before making an offer to acquire SUPG.
"Montigen was founded in 2003 by David J. Bearss, Ph.D. and Dallin M. Anderson, to further develop and commercialize research conducted by Dr. Bearss at the University of Arizona in collaboration with Dr. Daniel Von Hoff, MD, a scientific advisor to SuperGen and a member of Montigen's Scientific Advisory Board."